Alluvi, previously BI 4744, presents a significant advance in obesity treatment. This dual stimulator targeting both glucagon-like peptide-1 and GIP targets demonstrates compelling results in patient studies, arguably https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/